-
Pomalidomide (CC-4047) Research Workflows
2026-09-15
Use Pomalidomide (CC-4047) to connect cytokine modulation, genotype-aware myeloma models, and erythroid readouts in a disciplined research workflow. This guide emphasizes model selection, executable assay parameters, compound handling, and troubleshooting rather than treating one concentration or cell line as universally predictive.
-
HABA (4′-Hydroxyazobenzene-2-carboxylic acid)
2026-09-15
This scenario-based guide explains how HABA (4′-Hydroxyazobenzene-2-carboxylic acid), SKU B7918, can strengthen avidin–biotin surface characterization alongside cell viability, proliferation, and PLGA release workflows. It separates validated product facts from practical assay recommendations and shows how to interpret absorbance data without treating HABA as a substitute for a viability readout.
-
ARCA EGFP mRNA for Reliable Transfection Assays
2026-09-14
Learn how ARCA EGFP mRNA, SKU R1001, helps separate delivery and expression variability from true cytotoxicity in mammalian cell assays. This scenario-based guide covers reporter selection, handling, protocol optimization, data interpretation, and practical vendor evaluation.
-
Flumequine: Separating Growth Arrest from Cell Death
2026-09-14
Flumequine is a DNA topoisomerase II inhibitor that can anchor a more informative drug-response workflow. This article explains how to combine enzyme-level inhibition with separate measurements of proliferation and cell killing for stronger DNA replication research and cancer assay interpretation.
-
NAD+/NADH Homeostasis in Fungal Hypoxia
2026-09-13
This award review explains how NAD+/NADH balance coordinates hypoxic adaptation, fermentation, energy conservation, and secondary metabolite production in filamentous fungi. Its mechanistic framework helps researchers design redox-resolved experiments while clarifying why metabolic inhibitors must be interpreted in the context of oxygen availability and compensatory pathways.
-
QX77: Separating CMA from Mitophagy in Assays
2026-09-12
QX77 is a molecular chaperone activator for studying LAMP2A, Rab11, and chaperone-mediated autophagy without confusing CMA with mitophagy. This article uses the ETS1–SENP2–HSPA8–FUNDC1 study to develop a practical, mechanism-aware framework for autophagy pathway modulation and stem cell biology research.
-
Vasopressin Analogues: Design, Receptors, and Translation
2026-09-12
Glavaš and colleagues present a literature-based framework showing how structural changes to vasopressin alter receptor preference, proteolytic stability, duration of action, and therapeutic use. The review places lypressin, desmopressin, terlipressin, ornipressin, and non-peptide ligands within a translational continuum spanning treatment of diabetes insipidus, vascular pharmacology, and exploratory antiviral research.
-
Ridaforolimus: A Decision Framework for Senolysis
2026-09-11
Ridaforolimus and Deforolimus are potent mTOR-pathway tools for separating cancer-cell cytostasis from selective senescent-cell elimination. This article translates machine-learning senolytic discovery into practical assay design, controls, and interpretation.
-
Hepatic sEH–Nrf2 Signaling in Osteoporosis
2026-09-11
The reference study identifies a liver–bone mechanism in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, inflammatory signaling, and Nrf2-dependent osteoclast differentiation. By combining patient samples, ovariectomy-induced osteoporosis, liver-specific perturbation, cell culture, and transcriptomics, it provides a mechanistic framework for studying redox imbalance in bone remodeling.
-
SB525334 TGF-beta1 Receptor Inhibitor Guide
2026-09-10
A scenario-based guide to using SB525334 (TGF-beta1 receptor inhibitor), SKU A5602, in viability, proliferation, cytotoxicity, and fibrosis research workflows. It explains pathway-specific interpretation, solvent and storage controls, protocol optimization, data comparison, and practical vendor-selection criteria.
-
GRK Bias in M1 Receptor Signaling: BQCA Evidence
2026-09-10
A 2025 study used time-resolved BRET to define how GRK2/3 and GRK5/6 shape M1 receptor coupling to G proteins and β-arrestin 2. Its BQCA results show that allosteric modulation can alter both signaling-protein recruitment and apparent acetylcholine potency, while also revealing a potentially important role for constitutive GRK5/6 association.
-
From Viability Readout to Mechanism: CCK-8 Plus
2026-09-09
A translational framework for using Cell Counting Kit-8 (CCK-8) Plus to connect viable-cell measurement with inflammatory mechanism, assay validation, and drug-development decisions.
-
Annexin V-FITC/PI Apoptosis Assay Kit Guide
2026-09-09
The Annexin V-FITC/PI Apoptosis Assay Kit supports rapid separation of viable, early apoptotic, and late apoptotic or necrotic cells using phosphatidylserine externalization and membrane integrity as paired readouts. It is intended for research flow cytometry or fluorescence microscopy, not diagnostic, medical, fixed-cell, or unvalidated sample applications.
-
S-Adenosylhomocysteine in Radiation Assays
2026-09-08
Use S-Adenosylhomocysteine to test whether methylation pressure modifies radiation-associated neuronal differentiation rather than merely measuring cell loss. This ratio-aware workflow combines SAH exposure, SAM rescue, neurite analysis, and pathway-aware controls while separating established findings from testable extensions.
-
NETs in CML: TKI Effects and Vascular Risk
2026-09-07
The reference study shows that neutrophil extracellular trap formation is elevated in treatment-naive chronic myeloid leukemia and can be differentially altered by tyrosine kinase inhibitors. Its combination of patient-derived neutrophils and a BCR-ABL1-transduced neutrophil model provides a mechanistic framework for investigating how leukemic signaling and therapy may intersect with thrombo-inflammatory risk.